This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Design and rationale for RE-VERSE AD: A phase 3 st...
Journal

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.

Read time: 1 mins
Published:25th Mar 2020
Author: Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S et al.
Ref.:Thromb Haemost. 2015 Jul;114(1):198-205.
DOI:10.1160/TH15-03-0192.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest